Cargando…
Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor
CASE: A 39-year-old man with thymoma-associated acetylcholine receptor antibody myasthenia gravis (MG) presented with fevers, night sweats, abdominal pain and weight loss. Marked splenomegaly and intra-abdominal lymphadenopathy were found. Biopsies confirmed disseminated Mycobacterium genavense infe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119138/ https://www.ncbi.nlm.nih.gov/pubmed/35663588 http://dx.doi.org/10.1136/bmjno-2022-000285 |
_version_ | 1784710642476777472 |
---|---|
author | Chen, Jessie Nguyen, MaiAnh Hu, Hannah Cheong, Elaine Sean Riminton, D Reddel, Stephen |
author_facet | Chen, Jessie Nguyen, MaiAnh Hu, Hannah Cheong, Elaine Sean Riminton, D Reddel, Stephen |
author_sort | Chen, Jessie |
collection | PubMed |
description | CASE: A 39-year-old man with thymoma-associated acetylcholine receptor antibody myasthenia gravis (MG) presented with fevers, night sweats, abdominal pain and weight loss. Marked splenomegaly and intra-abdominal lymphadenopathy were found. Biopsies confirmed disseminated Mycobacterium genavense infection. Despite antimicrobials and reduced immunosuppressive medications, he worsened. We suspected a thymoma-associated cytokine inhibitory antibody. The addition of subcutaneous interferon-gamma (IFN-γ) induced clinical and radiological improvement. His antimicrobials were able to be ceased. MG remained stable. Subsequent testing demonstrated an endogenous interleukin-12 (IL-12) inhibitor, likely inhibiting the IL-12/IFN-γ axis crucial for defence against mycobacterial infections. DISCUSSION: This case illustrates the autoimmune manifestations that can occur with thymoma. It illustrates the benefit of exogenous IFN-γ in overcoming the immune deficit. In this case, its use did not exacerbate existing autoimmune disease or trigger others. We raise awareness of the need to consider cytokine pathway defects as a contributing factor to refractory atypical infections in patients with thymoma-associated MG. |
format | Online Article Text |
id | pubmed-9119138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-91191382022-06-04 Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor Chen, Jessie Nguyen, MaiAnh Hu, Hannah Cheong, Elaine Sean Riminton, D Reddel, Stephen BMJ Neurol Open Short Report CASE: A 39-year-old man with thymoma-associated acetylcholine receptor antibody myasthenia gravis (MG) presented with fevers, night sweats, abdominal pain and weight loss. Marked splenomegaly and intra-abdominal lymphadenopathy were found. Biopsies confirmed disseminated Mycobacterium genavense infection. Despite antimicrobials and reduced immunosuppressive medications, he worsened. We suspected a thymoma-associated cytokine inhibitory antibody. The addition of subcutaneous interferon-gamma (IFN-γ) induced clinical and radiological improvement. His antimicrobials were able to be ceased. MG remained stable. Subsequent testing demonstrated an endogenous interleukin-12 (IL-12) inhibitor, likely inhibiting the IL-12/IFN-γ axis crucial for defence against mycobacterial infections. DISCUSSION: This case illustrates the autoimmune manifestations that can occur with thymoma. It illustrates the benefit of exogenous IFN-γ in overcoming the immune deficit. In this case, its use did not exacerbate existing autoimmune disease or trigger others. We raise awareness of the need to consider cytokine pathway defects as a contributing factor to refractory atypical infections in patients with thymoma-associated MG. BMJ Publishing Group 2022-05-18 /pmc/articles/PMC9119138/ /pubmed/35663588 http://dx.doi.org/10.1136/bmjno-2022-000285 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Short Report Chen, Jessie Nguyen, MaiAnh Hu, Hannah Cheong, Elaine Sean Riminton, D Reddel, Stephen Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor |
title | Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor |
title_full | Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor |
title_fullStr | Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor |
title_full_unstemmed | Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor |
title_short | Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor |
title_sort | refractory mycobacterium genavense infection secondary to thymoma-associated endogenous il-12 inhibitor |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119138/ https://www.ncbi.nlm.nih.gov/pubmed/35663588 http://dx.doi.org/10.1136/bmjno-2022-000285 |
work_keys_str_mv | AT chenjessie refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor AT nguyenmaianh refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor AT huhannah refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor AT cheongelaine refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor AT seanrimintond refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor AT reddelstephen refractorymycobacteriumgenavenseinfectionsecondarytothymomaassociatedendogenousil12inhibitor |